Revolution Medicines reported positive Phase 3 results for its orally administered RAS-targeting inhibitor daraxonrasib in metastatic pancreatic ductal adenocarcinoma, with outcomes reportedly showing longer progression-free survival and overall survival versus standard chemotherapy. The readouts were described as doubling median overall survival in the trial’s overall population. The trial enrolled patients with pancreatic tumors spanning multiple RAS variants, including RAS G12 mutations and tumors without an identified RAS mutation. The company emphasized tolerability and the potential for daraxonrasib to become a new targeted option in a disease where prognosis remains poor. With additional regulatory steps expected after the top-line results, the data strengthen the case for RAS pathway targeting in PDAC and may influence future trial designs combining biomarker selection with direct inhibition of oncogenic signaling.